Published in Oncotarget on April 05, 2016
Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples. Oncotarget (2016) 0.77
Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy. Oncogenesis (2016) 0.76
An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy. Br J Cancer (2016) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res (2012) 15.84
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis (2004) 4.33
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Focal adhesion regulation of cell behavior. Biochim Biophys Acta (2004) 3.83
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol (2004) 3.45
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol (2011) 3.22
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut (2008) 2.68
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol (1998) 2.30
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol (2010) 2.00
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut (2012) 1.63
Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev (2008) 1.56
Merging microarray data from separate breast cancer studies provides a robust prognostic test. BMC Bioinformatics (2008) 1.48
Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology (2011) 1.40
An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36
Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg (2009) 1.35
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS One (2012) 1.12
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res (2012) 1.11
Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res (2002) 1.07
Protein degradation in the large intestine: relevance to colorectal cancer. Curr Issues Intest Microbiol (2000) 1.07
Quantifying discrimination of Framingham risk functions with different survival C statistics. Stat Med (2012) 1.06
Ongoing challenge of stage II colon cancer. J Clin Oncol (2011) 1.04
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer (2011) 1.04
Individual-level analysis of differential expression of genes and pathways for personalized medicine. Bioinformatics (2014) 0.95
Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer. Brief Bioinform (2015) 0.90
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving? Clin Cancer Res (2013) 0.85
Gene signatures of drug resistance predict patient survival in colorectal cancer. Pharmacogenomics J (2014) 0.82
Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 0.81
A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. Breast Cancer Res Treat (2013) 0.81
Evaluating the consistency of differential expression of microRNA detected in human cancers. Mol Cancer Ther (2011) 0.80
Modulation of heparan-sulphate/chondroitin-sulphate ratio by glycosaminoglycan biosynthesis inhibitors affects liver metastatic potential of tumor cells. Int J Cancer (1995) 0.79
Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. J Oncol Pract (2014) 0.78
Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked? J Clin Oncol (2010) 0.78
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget (2015) 0.97
Systematic interpretation of comutated genes in large-scale cancer mutation profiles. Mol Cancer Ther (2010) 0.81
Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients. PLoS One (2014) 0.76
Functional comparison between genes dysregulated in ulcerative colitis and colorectal carcinoma. PLoS One (2013) 0.76
Similar source of differential blood mRNAs in lung cancer and pulmonary inflammatory diseases: calls for improved strategy for identifying cancer-specific biomarkers. PLoS One (2014) 0.75
Common DNA methylation alterations of Alzheimer's disease and aging in peripheral whole blood. Oncotarget (2016) 0.75